 "Biocon gains as insulin facility in Malaysia gets GMP nod")
Biocon was up 5.3% to Rs 353 on BSE in early morning trade after the company’s insulin manufacturing facility in Malaysia received a Good Manufacturing Practices (GMP) compliance certificate from Europe’s drug regulator.
“Biocon’s subsidiary in Malaysia, Biocon Sdn. Bhd., has been issued Certificate of ‘GMP Compliance’ from Europe for its insulin manufacturing facility in Malaysia,” the company said in a regulatory filing.
The Malaysia facility was inspected by European Medicines Agency (EMA) in April 2017.
“The certificate of GMP compliance reflects that the agency considered the site to be in compliance with the principles and guidelines of Good Manufacturing Practices for active substances, sterile drug products and quality control testing operations,” it added.
The facility that employs over 600 professionals is designed to manufacture recombinant human insulin and insulin analogs to cater to the needs of people with diabetes in global markets.
At 09:39 AM; the stock was up 4% at Rs 347 on BSE, as compared to 0.25% rise in the S&P BSE Sensex. A combined 2.42 million shares changed hands on the counter on BSE and NSE so far.
“Biocon’s subsidiary in Malaysia, Biocon Sdn. Bhd., has been issued Certificate of ‘GMP Compliance’ from Europe for its insulin manufacturing facility in Malaysia,” the company said in a regulatory filing.
The Malaysia facility was inspected by European Medicines Agency (EMA) in April 2017.
“The certificate of GMP compliance reflects that the agency considered the site to be in compliance with the principles and guidelines of Good Manufacturing Practices for active substances, sterile drug products and quality control testing operations,” it added.
The facility that employs over 600 professionals is designed to manufacture recombinant human insulin and insulin analogs to cater to the needs of people with diabetes in global markets.
At 09:39 AM; the stock was up 4% at Rs 347 on BSE, as compared to 0.25% rise in the S&P BSE Sensex. A combined 2.42 million shares changed hands on the counter on BSE and NSE so far.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%